dc.contributor.author | Senturk, Hakan | |
dc.contributor.author | Ozaras, Resat | |
dc.contributor.author | Canbakan, Billur | |
dc.contributor.author | Mert, Ali | |
dc.contributor.author | Tabak, Fehmi | |
dc.contributor.author | Erdem, Levent | |
dc.contributor.author | Yurdakul, Ibrahim | |
dc.date.accessioned | 2021-03-03T18:52:53Z | |
dc.date.available | 2021-03-03T18:52:53Z | |
dc.date.issued | 2009 | |
dc.identifier.citation | Senturk H., Tabak F., Ozaras R., Erdem L., Canbakan B., Mert A., Yurdakul I., "Efficacy of Pre-S-containing HBV Vaccine Combined with Lamivudine in the Treatment of Chronic HBV Infection", DIGESTIVE DISEASES AND SCIENCES, cilt.54, sa.9, ss.2026-2030, 2009 | |
dc.identifier.issn | 0163-2116 | |
dc.identifier.other | av_518518d6-8f7f-43b4-b5de-bfd62dcc22ef | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/57958 | |
dc.identifier.uri | https://doi.org/10.1007/s10620-008-0586-2 | |
dc.description.abstract | Treatment of chronic hepatitis B (CHB) is difficult. The response rate to interferon (IFN) as well as nucleoside analogs is not more than 30% in general. While interferon has many side effects, development of resistance in most of the nucleoside analogs precludes long-term use. Both groups of drugs are most efficacious in patients who already had or develop strong cellular immunity with treatment. A pre-S2-containing vaccine was shown to enhance cellular immunity and suppress hepatitis B virus (HBV)-DNA in subjects with chronic hepatitis B. We aimed to test the efficacy of short-term use of a nucleoside analog in combination with a pre-S2-containing vaccine in patients with CHB. In this open study, 48 consecutive patients (32 males and 16 females, mean age +/- A SD: 33 +/- A 12 years) with CHB without cirrhosis were treated with 100 mg/day lamivudine and four weekly intramuscular injections of Genhevac B 20 mcg (six doses) for 24 weeks. While 19 patients were hepatitis B e antigen (HBeAg) positive (+ve), 29 patients were Anti-HBe/HBV-DNA +ve at the outset. Response was defined as seroconversion to anti-HBe in HBeAg +ve subjects and normalization of alanine aminotransferase (ALT) with loss of HBV-DNA in anti-HBe/HBV-DNA +ve subjects. HBeAg seroconversion occurred in 5/19 subjects (26%). Eighteen of 29 anti-HBe/HBV-DNA +ves responded. In the follow-up, while relapse was not observed in any of the patients who seroconverted, 11/18 from the anti-HBe/HBV-DNA +ve group relapsed, resulting in a sustained response (SR) rate of 24% in this group. All the relapses happened in the first 48 weeks of follow-up, with no relapse thereafter. Pretreatment high serum HBV-DNA was a strong negative predictor of sustained response (SR) in HBeAg +ve group. Pretreatment serum ALT over 2 x upper limit of normal and HBV-DNA less than 200 pg/ml appeared positive predictors. None of HBeAg +ve previous interferon failures responded. Twenty-four weeks of lamivudine and hepatitis B vaccine treatment induces SR in around 1/4 of the patients with CHB. Most of the responders had high ALT and relatively low DNA. | |
dc.language.iso | eng | |
dc.subject | Gastroenteroloji-(Hepatoloji) | |
dc.subject | Sağlık Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | GASTROENTEROLOJİ VE HEPATOLOJİ | |
dc.title | Efficacy of Pre-S-containing HBV Vaccine Combined with Lamivudine in the Treatment of Chronic HBV Infection | |
dc.type | Makale | |
dc.relation.journal | DIGESTIVE DISEASES AND SCIENCES | |
dc.contributor.department | Istanbul Sisli Hamidiye Etfal Training & Research Hospital , , | |
dc.identifier.volume | 54 | |
dc.identifier.issue | 9 | |
dc.identifier.startpage | 2026 | |
dc.identifier.endpage | 2030 | |
dc.contributor.firstauthorID | 41227 | |